Emergent BioSolutions | EBS - Umlaufvermögen





Umlaufvermögen Veränderung Datum
Acadia Pharmaceuticals USD 1.06B 14.31M 2025-12
Akebia Therapeutics USD 252.96M 5.38M 2025-12
ALKERMES USD 1.93B 187.5M 2025-12
Alnylam Pharmaceuticals USD 4.05B 97.85M 2025-12
Amarin USD 649.88M 21.55M 2025-12
ANI Pharmaceuticals USD 753.12M 54.72M 2025-12
BioMarin Pharmaceutical USD 3.95B 98.95M 2025-12
Coherus Biosciences USD 206.71M 254.25M 2025-12
Emergent BioSolutions USD 679.5M 41.3M 2023-12
Exelixis USD 1.44B 41.03M 2025-12
Glaxosmithkline GBP 23.59B 390.44M 2025-12
Heron Therapeutics USD 238.07M 8.67M 2025-12
Ionis Pharmaceuticals USD 2.99B 471.01M 2025-12
Ironwood Pharmaceuticals USD 273.84M 82.09M 2025-09
Lexicon Pharmaceuticals USD 101.9M 20.63M 2025-12
Lonza CHF 8B 3.41B 2025-12
Merck USD 47.56B 10.49B 2025-09
Moderna USD 6.54B 54M 2025-12
Myriad Genetics USD 332.6M 12.2M 2025-12
Nektar Therapeutics USD 266.27M 15.09M 2025-12
Neurocrine Biosciences USD 2.52B 364.3M 2025-12
Pacira USD 547.97M 14.78M 2025-12
Pfizer USD 46.92B 3.22B 2025-09
PTC Therapeutics USD 2.27B 266.14M 2025-12
Sanofi EUR 30.16B 789M 2026-03
Sarepta Therapeutics USD 2.54B 184.37M 2025-12
United Therapeutics USD 3.7B 208.5M 2025-12
Vanda Pharmaceuticals USD 347.26M 20.23M 2025-12
Xoma USD 110.71M 5.78M 2025-09